No evidence for xenotropic murine leukemia-related virus infection in sweden using internally controlled multiepitope suspension array serology

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1399-1410

  Blomberg, Jonas ^a   Blomberg, Fredrik ^a   Sjösten, Anna ^a   Sheikholvaezin, Ali ^a   Bölin Wiener, Agnes ^a   Elfaitouri, Amal ^a   Hessel, Sanna ^a   Gottfries, Carl Gerhard ^b   Zachrisson, Olof ^b   Öhrmalm, Christina ^a,c   Jobs, Magnus ^a,d   Pipkorn, Rüdiger ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b Gottfries Clinic AB   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN G; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; ENVELOPE GENE; GOAT; GROUP SPECIFIC ANTIGEN GENE; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIEPITOPE SUSPENSION ARRAY SEROLOGY; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RETROVIRUS INFECTION; SEROLOGY; SWEDEN; VIRUS GENE; XENOTROPIC MULV RELATED VIRUS; XENOTROPIC MURINE LEUKEMIA RELATED VIRUS INFECTION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; HUMANS; IMMUNOGLOBULIN G; MICROARRAY ANALYSIS; RECOMBINANT PROTEINS; RETROVIRIDAE INFECTIONS; SEROLOGIC TESTS; SWEDEN; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS;

EID: 84865970082     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00391-12     Document Type: Article

References (77)

1. Ablashi DV, et al. 1991. Human herpesvirus 6 (HHV6) and chronic fatigue syndrome (CFS). Can. Dis. Wkly. Rep. 17(Suppl. 1E):33-40.
2. Alberts B. 2011. Retraction. Science 334:1636.
3. Albino AP, et al. 1986. Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses. J. Exp. Med. 164:1710-1722. (Pubitemid 17184199)
4. Andersson S, et al. 1995. HTLV infections among Swedish intravenous drug users in 1992. Scand. J. Infect. Dis. 27:547-550. (Pubitemid 26089483)
5. Antonsson A, et al. 2010. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J. Gen. Virol. 91:1849-1853.
6. Arnold RS, et al. 2010. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology 75: 755-761.
7. Blaise S, Mangeney M, Heidmann T. 2001. The envelope of Mason- Pfizer monkey virus has immunosuppressive properties. J. Gen. Virol. 82:1597-1600. (Pubitemid 32611500)
8. Blomberg J, et al. 1993. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera. AIDS 7:759-767. (Pubitemid 23212440)
9. Blomberg J, Nilsson I, Andersson M. 1983. Viral antibody screening system that uses a standardized single dilution immunoglobulin G enzyme immunoassay with multiple antigens. J. Clin. Microbiol. 17:1081-1091. (Pubitemid 13098872)
10. Blomberg J, Robert-Guroff M, Blattner WA, Pipkorn R. 1992. Type-and group-specific continuous antigenic determinants of HTLV. Use of synthetic peptides for serotyping of HTLV-I and -II infection. J. Acquir. Immune Defic. Syndr. 5:294-302.
11. Blomberg J, et al. 2011. Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer. Adv. Virol. 2011:341294.
12. Cameron B, et al. 2010. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome. J. Med. Virol. 82:1684-1688.
13. Carruthers BM. 2007. Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works. J. Clin. Pathol. 60:117-119.
14. Carruthers BM, et al. 2011. Myalgic encephalomyelitis: international consensus criteria. J. Intern. Med. 270:327-338.
15. Chia J, Chia A, Voeller M, Lee T, Chang R. 2010. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J. Clin. Pathol. 63:165-168.
16. Chiang CY, Chang JT, Lin MS, Wang SR, Chang HY. 2005. Characterization of a monoclonal antibody specific to the Gag protein of porcine endogenous retrovirus and its application in detecting the virus infection. Virus Res. 108:139-148.
17. Coffin JM, Hughes SH, Varmus HE (ed). 1997. Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
18. DeFreitas E, et al. 1991. Retroviral sequences related to human Tlymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc. Natl. Acad. Sci. U. S. A. 88:2922-2926. (Pubitemid 21916532)
19. DeLeo AB, et al. 1982. Possible role of a retrovirus in the expression of tumor-specific antigens of the MethAsarcoma. Int. J. Cancer 29:687-693. (Pubitemid 12089210)
20. Dong B, et al. 2007. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl. Acad. Sci. U. S. A. 104:1655-1660. (Pubitemid 46214646)
21. Earl PL, et al. 1986. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 234:728-731. (Pubitemid 17184218)
22. Elberse KE, Tcherniaeva I, Berbers GA, Schouls LM. 2010. Optimization and application of a multiplex bead-based assay to quantify serotypespecific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin. Vaccine Immunol. 17:674-682.
23. Elfaitouri A, et al. 2011. Murine gammaretrovirus group g3 was not found in Swedish patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. PLoS One 6:e24602. doi:10.1371/journal.pone.0024602.
24. Eligio P, Delia R, Valeria G. 2010. EBV chronic infections. Mediterr. J. Hematol. Infect. Dis. 2:e2010022. doi:10.4084/MJHID.2010.022.
25. Fukuda K, et al. 1994. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121:953-959. (Pubitemid 24370860)
26. Furuta RA, et al. 2011. No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology 8:20.
27. Geering G, Hardy WD, Jr, Old LJ, de Harven E, Brodey RS. 1968. Shared group-specific antigen of murine and feline leukemia viruses. Virology 36:678-680.
28. Groom HC, et al. 2010. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 7:10. doi:10.1186/1742-4690-7-10.
29. Hardy WD, Jr, et al. 1969. Feline leukemia virus: occurrence of viral antigen in the tissues of cats with lymphosarcoma and other diseases. Science 166:1019-1021.
30. Heiligenberg M, et al. 2010. Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sex. Transm. Dis. 37:672-680.
31. Hohn O, et al. 2009. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology 6:92. doi:10.1186/1742-4690-6-92.
32. Hohn O, et al. 2010. No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One 5:e15632. doi:10.1371/journal.pone.0015632.
33. Kerr JR. 2008. Enterovirus infection of the stomach in chronic fatigue syndrome/myalgic encephalomyelitis. J. Clin. Pathol. 61:1-2. (Pubitemid 351158217)
34. Khan IH, et al. 2010. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay Drug Dev. Technol. 8:27-36.
35. Klasse PJ, Pipkorn R, Blomberg J. 1988. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc. Natl. Acad. Sci. U. S. A. 85:5225-5229.
36. Krook A, Blomberg J. 1994. HTLV-II among injecting drug users in Stockholm. Scand. J. Infect. Dis. 26:129-132. (Pubitemid 24141095)
37. Langhammer S, Fiebig U, Kurth R, Denner J. 2005. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 23:3341-3348. (Pubitemid 40523129)
38. Lombardi VC, et al. 2009. Detection of an infectious retrovirus,XMRV,in blood cells of patients with chronic fatigue syndrome. Science 326:585-589.
39. Lostrom ME, et al. 1979. Monoclonal antibodies against murine leukemia viruses: identification of six antigenic determinants on the p 15(E) and gp70 envelope proteins. Virology 98:336-350. (Pubitemid 10191214)
40. Makarova N, et al. 2011. Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model. PLoS One 6:e18272. doi:10.1371/journal.pone.0018272.
41. Mangeney M, Heidmann T. 1998. Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc. Natl. Acad. Sci. U. S. A. 95:14920-14925. (Pubitemid 29003732)
42. Mikovits JA, et al. 2010. Distribution of xenotropic murine leukemia virus-related virus (XMRV) infection in chronic fatigue syndrome and prostate cancer. AIDS Rev. 12:149-152.
43. Miyazawa M, Fujisawa R. 1994. Physiology and pathology of host immune responses to exogenous and endogenous murine retroviruses - from gene fragments to epitopes. Tohoku J. Exp. Med. 173:91-103.
44. Nick S, et al. 1990. Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence. J. Gen. Virol. 71:77- 83.
45. Nowinski RC, Pickering R, O'Donnell PV, Pinter A, Hammerling U. 1981. Selective neutralization of ecotropic murine leukemia virus by monoclonal antibodies: localization of a site on the gp70 protein associated with ecotropism. Virology 111:84-92. (Pubitemid 11047680)
46. Old LJ, Boyse EA. 1965. Antigens of tumors and leukemias induced by viruses. Fed Proc. 24:1009-1017.
47. Ono T, et al. 2000. Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen. Int. J. Cancer 88:845-851.
48. Pheby D, et al. 2011. A disease register for ME/CFS: report of a pilot study. BMC Res. Notes 4:139. doi:10.1186/1756-0500-4-139.
49. Pickering JW, Larson MT, Martins TB, Copple SS, Hill HR. 2010. Elimination of false-positive results in a Luminex assay for pneumococcal antibodies. Clin. Vaccine Immunol. 17:185-189.
50. Pinter A, Honnen WJ. 1984. Characterization of structural and immunological properties of specific domains of Friend ecotropic and dualtropic murine leukemia virus gp70s. J. Virol. 49:452-458. (Pubitemid 14221318)
51. Pinter A, Honnen WJ. 1983. Topography of murine leukemia virus envelope proteins: characterization of transmembrane components. J. Virol. 46:1056-1060. (Pubitemid 13092516)
52. Pinter A, Honnen WJ, Tung JS, O'Donnell PV, Hammerling U. 1982. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology 116:499-516. (Pubitemid 12163303)
53. Prins JB, Bleijenberg G, van der Meer JW. 2002. Chronic fatigue syndrome and myalgic encephalomyelitis. Lancet 359:1699.
54. Qiu X, et al. 2010. Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. Retrovirology 7:68. doi:10.1186/1742-4690-7-68.
55. Qiu X, et al. 2012. Seroprevalence of xenotropic murine leukemia virus-related virus in normal and retrovirus-infected blood donors. Transfusion 52:307-316.
56. Rucheton M, et al. 1985. Presence of circulating antibodies against gaggene MuLV proteins in patients with autoimmune connective tissue disorders. Virology 144:468-480. (Pubitemid 15247652)
57. Rucheton M, Graafland H, Valles H, Larsen CJ. 1987. Human autoimmune serum antibodies against gag gene p30 retroviral protein also react with a U1-SnRNP 68K comigrant protein. Biol. Cell 60:71-72.
58. Rusmevichientong A, Das Gupta J, Elias PS, Silverman RH, Chow SA. 2011. Analysis of single-nucleotide polymorphisms in patient-derived retrovirus integration sites reveals contamination from cell lines acutely infected by xenotropic murine leukemia virus-related virus. J. Virol. 85: 12830-12834.
59. Sakuma T, et al. 2011. No evidence of XMRV in prostate cancer cohorts in the midwestern United States. Retrovirology 8:23. doi:10.1186/1742-4690-8-23.
60. Sakuma T, et al. 2011. Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J. Virol. 85:1205-1213.
61. Sheikholvaezin A, Blomberg F, Ohrmalm C, Sjosten A, Blomberg J. 2011. Rational recombinant XMRV antigen preparation and bead coupling for multiplex serology in a suspension array. Protein Expr. Purif. 80:176-184.
62. Shoma S, et al. 2011. Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins. Eur. J. Clin. Microbiol. Infect. Dis. 30:521-526.
63. Sijts EJ, et al. 1994. Cloning of the MCF1233 murine leukemia virus and identification of sequences involved in viral tropism, oncogenicity and T cell epitope formation. Virus Res. 34:339-349. (Pubitemid 24360583)
64. Silverman RH, et al. 2011. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 334:176.
65. Simmons G, et al. 2011. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 334:814-817.
66. Stieler K, et al. 2011. No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS One 6:e25592. doi:10.1371/journal.pone.0025592.
67. Switzer WM, et al. 2010. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 7:57. doi: 10.1186/1742-4690-7-57.
68. Urisman A, et al. 2006. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2:e25. doi:10.1371/journal.ppat.0020025.
69. Waterboer T, Sehr P, Pawlita M. 2006. Suppression of non-specific binding in serological Luminex assays. J. Immunol. Methods 309:200-204. (Pubitemid 43190816)
70. Weijer K, et al. 1993. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Vaccine 11:946-956. (Pubitemid 23218804)
71. Weijer K, Uytdehaag FG, Osterhaus AD. 1989. Control of feline leukaemia virus. Vet. Immunol. Immunopathol. 21:69-83. (Pubitemid 19189774)
72. Westgard JO. 2003. Internal quality control: planning and implementation strategies. Ann. Clin. Biochem. 40:593-611. (Pubitemid 37421705)
73. Westgard JO, Barry PL, Hunt MR, Groth T. 1981. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin. Chem. 27:493-501.
74. Wolfe F, et al. 1990. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33:160-172. (Pubitemid 20098653)
75. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG. 2002. A rating scale for fibromyalgia and chronic fatigue syndrome (the Fibro-Fatigue scale). J. Psychosom. Res. 52:501-509. (Pubitemid 34759879)
76. Zhang L, et al. 2010. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J. Clin. Pathol. 63:156-164.
77. Zhou Y, et al. 2012. Development and application of a high-throughput microneutralization assay: lack of xenotropic murine leukemia virus-related virus and/or murine leukemia virus detection in blood donors. Transfusion 52:332-342.